{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-045401","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.834697+00:00","generated_at":"2026-06-10T08:27:14.381092+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's","bullets":["Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.","Ionis responsible for pre-clinical advancement; Roche leads clinical development, manufacturing, and commercialization.","Ionis eligible for development, regulatory, and commercial milestone payments plus tiered royalties.","Programs target Alzheimer's disease and Huntington's disease; expands 10-year partnership including tominersen for HD."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-045401","json":"https://secwatch.observer/filing/0001140361-23-045401.json","markdown":"https://secwatch.observer/filing/0001140361-23-045401.md","text":"https://secwatch.observer/filing/0001140361-23-045401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/0001140361-23-045401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/ef20011349_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:27:14.381092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"445d0944537da9f946c797206efae0067b1c4269","claim":"IONIS PHARMACEUTICALS INC entered into a collaboration with Roche (effective 2023-09-27).","evidence_excerpt":"On September 27, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into an agreement with Roche for two early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease and Huntington’s disease.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/0001140361-23-045401-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Roche"},{"label":"Effective","value":"2023-09-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}